Free Trial
NASDAQ:ARWR

Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

Arrowhead Pharmaceuticals logo
$18.79 +0.25 (+1.35%)
(As of 11/25/2024 ET)

About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)

Key Stats

Today's Range
$18.73
$19.84
50-Day Range
$17.70
$21.97
52-Week Range
$17.05
$39.83
Volume
1.51 million shs
Average Volume
1.20 million shs
Market Capitalization
$2.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.33
Consensus Rating
Moderate Buy

Company Overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
72nd Percentile Overall Score

ARWR MarketRank™: 

Arrowhead Pharmaceuticals scored higher than 72% of companies evaluated by MarketBeat, and ranked 298th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arrowhead Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about Arrowhead Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Arrowhead Pharmaceuticals are expected to grow in the coming year, from ($4.31) to ($3.80) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arrowhead Pharmaceuticals is -4.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arrowhead Pharmaceuticals is -4.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arrowhead Pharmaceuticals has a P/B Ratio of 7.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Arrowhead Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    7.55% of the outstanding shares of Arrowhead Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Arrowhead Pharmaceuticals has recently increased by 0.64%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Arrowhead Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Arrowhead Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.55% of the outstanding shares of Arrowhead Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Arrowhead Pharmaceuticals has recently increased by 0.64%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Arrowhead Pharmaceuticals has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Arrowhead Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    Only 4 people have searched for ARWR on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arrowhead Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.50% of the stock of Arrowhead Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arrowhead Pharmaceuticals' insider trading history.
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Stock News Headlines

Arrowhead climbs after licensing deal with Sarepta
Is NVDA a sell? Buy this stock instead before Dec 3
After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is making headlines for last week's new earnings report – which revealed the AI juggernaut nearly doubled their profits in the last year alone.
Reviewing PaxMedica (NASDAQ:PXMD) & Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Tuesday
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Buy Rating at HC Wainwright
See More Headlines

ARWR Stock Analysis - Frequently Asked Questions

Arrowhead Pharmaceuticals' stock was trading at $30.60 at the beginning of the year. Since then, ARWR stock has decreased by 38.6% and is now trading at $18.79.
View the best growth stocks for 2024 here
.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its earnings results on Thursday, August, 8th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.80. The business's revenue was down 100.0% on a year-over-year basis.

Arrowhead Pharmaceuticals' top institutional shareholders include State Street Corp (5.11%), FMR LLC (4.88%), Geode Capital Management LLC (2.38%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.73%). Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Martin Javier San, Douglas B Given, Tracie Oliver, Hongbo Lu, Victoria Vakiener, William D Waddill and Adeoye Y Olukotun.
View institutional ownership trends
.

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alliance Resource Partners (ARLP), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Netflix (NFLX).

Company Calendar

Last Earnings
8/08/2024
Today
11/26/2024
Next Earnings (Confirmed)
11/26/2024
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARWR
Employees
400
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$45.33
High Stock Price Target
$62.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+141.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$-205,270,000.00
Pretax Margin
-2,792.41%

Debt

Sales & Book Value

Annual Sales
$19.65 million
Book Value
$2.68 per share

Miscellaneous

Free Float
118,721,000
Market Cap
$2.34 billion
Optionable
Optionable
Beta
0.93

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:ARWR) was last updated on 11/26/2024 by MarketBeat.com Staff
From Our Partners